|
To: Maine Immunization Program Providers
From: Maine Immunization Program
Subject: UPDATED - Interim Clinical Considerations for COVID-19 Vaccines
Date: April 24, 2023
The U.S. CDC has updated the Interim Clinical Considerations for COVID-19 Vaccines. All information is current as of April 22, 2023.
Updates include:
- At the time of initial vaccination, depending on vaccine product:
- children ages 6 months–4 years are recommended to receive 2 or 3 bivalent mRNA vaccine doses.
- children aged 5 years are recommended to receive 1 or 2 bivalent mRNA vaccine doses.
- People ages 6 years and older who are unvaccinated or previously received only monovalent vaccine doses are recommended to receive 1 bivalent mRNA vaccine dose.
- People ages 65 years and older may receive 1 additional bivalent mRNA vaccine dose.
- CDC’s new recommendations allow an additional updated (bivalent) vaccine dose for adults ages 65 years and older and additional doses for people who are immunocompromised. This allows more flexibility for healthcare providers to administer additional doses to immunocompromised patients as needed.
- Alternatives to mRNA COVID-19 vaccines remain available for people who cannot or will not receive an mRNA vaccine. CDC’s recommendations for use of (monovalent) Novavax or Johnson & Johnson’s Janssen COVID-19 vaccines were not affected by recent changes.
Additional Resources:
COVID-19 Vaccination Clinical and Professional Resources | CDC
U.S. COVID-19 Vaccine Product Information | CDC
Pfizer-BioNTech COVID-19 Vaccines | FDA
Moderna COVID-19 Vaccines | FDA
Should you have any questions, please contact us at (207) 287-3746 or email: ImmunizeME.DHHS@maine.gov.
Thank you for your continued efforts to ensure all Mainers have access to COVID-19 vaccination.
|
